Skip to content
Home » Lower pregnancy risks in women who received the HPV vaccine

Lower pregnancy risks in women who received the HPV vaccine


A national case-control study from Sweden showed lower risks of preterm, very preterm, or spontaneous preterm birth during pregnancy in women who received the HPV vaccine. The links were even stronger in those who received the vaccine before age 17 when it came to preterm birth and spontaneous preterm birth.

This study shows that the benefits of the HPV vaccine not only go beyond just preventing an infection, but it also may reduce the risks of negative pregnancy outcomes.

This post reviews the new study and lists a couple of reasons the vaccine may have these effects.

All about HPV and the HPV vaccine

I know I cut and paste this section into every article I write about HPV vaccines, but it’s the first step to HPV vaccine myth debunking. Some readers may be researching the vaccine for the first time, and this provides the basics about the disease and vaccine.

However, I update this section as needed with new information about the disease or the vaccine. If you’ve read this section 47 times, skip to the next section where I discuss the key points of this article.

Genital and oral human papillomavirus (HPV) infections are the most common sexually transmitted infections (STIs) in the USA. HPV is generally transmitted through personal contact during vaginal, anal, or oral sex.

It is critical to note that there are more than 150 strains or subtypes of HPV that can infect humans; however, only 40 of these strains are linked to one or more different cancers. Moreover, most of those 40 strains are fairly rare.

Although the early symptoms of HPV infections aren’t serious and many HPV infections resolve themselves without long-term harm, HPV infections are causally linked to many types of cancers in men and women. According to current medical research, here are some of the cancers that are linked to HPV:

In addition, there is some evidence that HPV infections are causally linked to skin and prostate cancers. The link to skin cancer is still preliminary, but there is much stronger evidence that HPV is linked to many prostate cancers.

HPV is believed to cause nearly 5% of all new cancers across the world, making it almost as dangerous as tobacco in that respect. According to published research, roughly 42 million persons in the USA are infected with disease-associated HPV, and 13 million persons acquire a new infection each year.

Most individuals don’t even know they have the infection until the onset of cancer. The CDC states that over 37,800 HPV-related cancers are diagnosed in the USA every year. In 2022, there were approximately 1,505,394 HPV-related cancer cases and 755,303 deaths worldwide, with cervical cancer being the primary cause, accounting for 14.1 per 100,000 people.

Two HPV vaccines were on the world market before 2014. GSK, also known as GlaxoSmithKline, produced Cervarix, a bivalent vaccine that protects only against two HPV strains. Cervarix has been withdrawn from the US market (though it remains available in many other markets) because of competition from the quadrivalent vaccine, which immunizes against four HPV strains, and the 9-valent vaccine, Gardasil, which protects against nine HPV strains.

Merck manufactures Gardasil, the most common HPV vaccine. The first version of the vaccine, quadrivalent Gardasil, targeted the two HPV genotypes known to cause about 70% of cervical cancer and two other HPV genotypes that cause genital warts. In Europe and other markets, Gardasil is known as Silgard.

The newer Gardasil 9, approved by the FDA in 2014, is a 9-valent vaccine that protects against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. It targets the four HPV strains found in the quadrivalent version, along with five additional ones that are linked to cervical and other HPV-related cancers. Both versions of Gardasil are prophylactic, meant to be given to females or males before they become exposed to possible HPV infection through intimate contact.

Gardasil is one of the easiest and best ways to prevent a few dangerous and, to abuse the definition slightly, common cancers that afflict men and women. Without a doubt, the HPV vaccine prevents cancer.

In the United States, the Advisory Committee on Immunization Practices (ACIP) currently recommends that preteen girls and boys aged 11 or 12 receive the HPV vaccine. The HPV vaccine is also recommended for teenage girls and young women up to the age of 26 who did not receive it when they were younger, and boys and young men up to the age of 21.

HPV is a sexually transmitted disease. HPV causes 37,800 cancers a year in the USA and over 1.5 million worldwide. The HPV vaccine prevents you from becoming infected with HPV, which means you are protected from these cancers.

colored liquids on flasks
Photo by cottonbro studio on Pexels.com

Lower pregnancy risks after HPV vaccine paper

In a paper published on 7 October 2026 in BMJ, Jiayao Lei, PhD, Karolinska Institute, Stockholm, and colleagues studied 624,713 singleton births from 2006 to 2023 in Sweden among women who had not previously given birth, aged 16 to 35 years, using data from nationwide registers. Among eligible births, 14.8% of women had received the quadrivalent HPV vaccine before pregnancy.

The researchers excluded births from women whose first HPV vaccine was bivalent (Cervarix) or nonavalent (Gardasil 9). To help counter confounding, the researchers matched each adverse pregnancy outcome case with up to 10 controls without the same adverse outcomes.

Here are the key results:

  • Women who had received a quadrivalent HPV vaccination had a statistically significant 5% lower odds of preterm birth.
  • Vaccinated women had a 15% lower risk of very preterm birth.
  • They had a 5% lower risk of spontaneous preterm birth.
  • When HPV vaccination happened before age 17, it was associated with 10% lower odds of preterm birth and 11% lower risk of spontaneous preterm birth (aOR 0.89, 95% CI 0.84-0.95) compared with women who were unvaccinated.
  • Vaccinated women were 7% less likely to have preterm prelabor rupture of membranes or an 8% lower risk of a severe small-for-gestational-age infant.
HPV vaccine pregnancy

Summary

Although these results are small, they are statistically significant because the study included a large number of women (over 620,000). Of course, the question is why the HPV vaccine would have a link to lower pregnancy risks.

The researchers proposed two reasons why the vaccine has this effect:

  1. HPV may interfere with embryonic development, which could lead to placental problems and greater preterm birth risk. HPV vaccination could also reduce the risk of fetal HPV exposure, which could lead to pregnancy complications.
  2. Other research has shown that treatment for HPV-related high-grade cervical lesions is associated with greater risks of preterm birth and other negative pregnancy outcomes. In the Zhang et al. study, 0.6% of vaccinated women and 3.7% of unvaccinated women had a diagnosis of a high-grade cervical lesion.

This study provides more powerful evidence that the HPV vaccine benefits beyond just preventing HPV infections and HPV-linked cancers. These are simply more reasons to get the vaccine and get it early.

Citations

Help the Skeptical Raptor keep writing about vaccines

There are four ways you can help contribute to keeping this website running at full speed:

  1. GoFundMe.
  2. Subscribing via Patreon.
  3. Buying your favorite stuff on Amazon.
  4. Sharing this article on Social Media.

Don’t miss each new article!

We don’t spam! Read our privacy policy for more info.

Liked it? Take a second to support Michael Simpson on Patreon!
Become a patron at Patreon!


Discover more from Skeptical Raptor

Subscribe to get the latest posts sent to your email.

Discover more from Skeptical Raptor

Subscribe now to keep reading and get access to the full archive.

Continue reading